Company news
Rapport Therapeutics, Inc. news in 2025
Rapport Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 4, 2025
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
November 24, 2025
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
November 5, 2025
Rapport Therapeutics to Participate in Upcoming Investor Conferences
November 4, 2025
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
September 10, 2025
Rapport Announces Pricing of Public Offering of Common Stock
September 8, 2025
Rapport Announces Proposed Public Offering of Common Stock
September 7, 2025
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
September 7, 2025
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
September 4, 2025
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
August 6, 2025
Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates
June 1, 2025
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
May 26, 2025
Rapport Therapeutics to Host 2025 Investor and Analyst Day
May 20, 2025
Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
May 7, 2025
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
March 20, 2025
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 10, 2025
Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development
March 2, 2025
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders
January 8, 2025
Decks in 2025
- Technical Presentation (September 2025)
Technical · 22 slides · Sep 8, 2025
- Investor Presentation (August 2025)
Investor deck · 32 slides · Aug 7, 2025
- Investor Day (June 2025)
Investor day · 46 slides · Jun 2, 2025
- Investor Presentation (March 2025)
Investor deck · 38 slides · Mar 3, 2025